Volume 7, Issue 1

SVR and Extrahepatic Manifestations

In this issue:

While the hepatic manifestations of hepatitis C infection (HCV) (eg, cirrhosis and liver cancer) are well known, the extrahepatic manifestations are also common and similarly contribute to significant morbidity and mortality. How has identification and management of these conditions changed in this era of more readily achieved sustained virologic response?

In this issue, Dr. Rajender Reddy from the Perelman School of Medicine at the University of Pennsylvania analyzes the current state of knowledge about the extrahepatic manifestations of chronic HCV and the impact of sustained virologic response after HCV therapy.

Learning objectives:

  • Assess the burden, consequences, and impact of hepatitis C antiviral therapy on the extrahepatic manifestations of chronic hepatitis C.
  • Describe the extrahepatic manifestations of chronic hepatitis C.
  • Explain the impact of sustained virologic response after hepatitis C therapy.


Rajender Reddy, MD
Rajender Reddy, MD

Ruimy Family President’s Distinguished Professor of Medicine; Director, Hepatology; Medical Director, Liver Transplantation
Perelman School of Medicine; University of Pennsylvania
Philadelphia, PA

Program Directors:

Mark S. Sulkowski, MD

Professor of Medicine
Division of Infectious Diseases
Medical Director, Viral Hepatitis Center
Divisions of Infectious Diseases and Gastroenterology and Hepatology
Johns Hopkins School of Medicine
Baltimore, Maryland

Raymond T. Chung, MD

Director of Hepatology and Liver Center
Vice Chief, Gastroenterology
Kevin and Polly Maroni Research Scholar
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts

Taryn Haselhuhn, BA, BSN, MSN, CRNP

The Johns Hopkins Hospital
​Baltimore, Maryland

Length of activity:

1.0 hour Physicians
1.0 contact hour Nurses

Launch date: February 14, 2020
Expiration date: February 13, 2022